Novartis: Dyspnea trials

The registry lists 14 Dyspnea studies with Novartis as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 2 7Phase 3 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe AsthmaCompletedNCT03299686Phase 2Results posted
• Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.CompletedNCT03257995Phase 2Results posted
• Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in AsthmaCompletedNCT03137784Phase 2/3Results posted
• Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With AsthmaCompletedNCT03108027Phase 2Results posted
• A Long-term Safety Study of QVM149 in Japanese Patients With AsthmaCompletedNCT03100825Phase 3Results posted
• A Long-term Safety Study of QMF149 in Japanese Participants With AsthmaCompletedNCT03100500Phase 3Results posted
• Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma TreatmentTerminatedNCT03052517Phase 3Results posted
• Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH PatientsTerminatedNCT02939599Phase 2Results posted
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH PatientsTerminatedNCT02927366Phase 2Results posted
• Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.CompletedNCT02555683Phase 3Results posted
• Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent AsthmaCompletedNCT01959412Phase 2Results posted
• The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01490125Phase 3Results posted
• Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00821093Phase 3Results posted
• Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHFWithdrawnNCT04592380Phase 3